Bioceltix S.A. (BCX.WA)

PLN 79.8

(4.04%)

Long Term Debt Summary of Bioceltix S.A.

  • Bioceltix S.A.'s latest annual long term debt in 2023 was 76.33 Thousand PLN , down -57.15% from previous year.
  • Bioceltix S.A.'s latest quarterly long term debt in 2024 Q2 was 60.58 Thousand PLN , down 0.0% from previous quarter.
  • Bioceltix S.A. reported annual long term debt of 178.14 Thousand PLN in 2022, up 18.84% from previous year.
  • Bioceltix S.A. reported annual long term debt of 149.91 Thousand PLN in 2021, up 300.91% from previous year.
  • Bioceltix S.A. reported quarterly long term debt of 60.58 Thousand PLN for 2024 Q2, down 0.0% from previous quarter.
  • Bioceltix S.A. reported quarterly long term debt of 76.33 Thousand PLN for 2023 FY, down -57.15% from previous quarter.

Annual Long Term Debt Chart of Bioceltix S.A. (2023 - 2018)

Historical Annual Long Term Debt of Bioceltix S.A. (2023 - 2018)

Year Long Term Debt Long Term Debt Growth
2023 76.33 Thousand PLN -57.15%
2022 178.14 Thousand PLN 18.84%
2021 149.91 Thousand PLN 300.91%
2020 37.39 Thousand PLN 0.0%
2019 - PLN 0.0%
2018 - PLN 0.0%

Peer Long Term Debt Comparison of Bioceltix S.A.

Name Long Term Debt Long Term Debt Difference
BIOTON S.A. 12.67 Million PLN 99.398%
Captor Therapeutics Spolka Akcyjna 1.24 Million PLN 93.879%
Mabion S.A. 2.94 Million PLN 97.411%
Molecure S.A. 4.97 Million PLN 98.466%
NanoGroup S.A. - PLN -Infinity%
Pharmena S.A. 114 Thousand PLN 33.041%
Poltreg S.A. 7.8 Million PLN 99.021%
Pure Biologics Spólka Akcyjna 12.85 Million PLN 99.406%
Ryvu Therapeutics S.A. 365 Thousand PLN 79.087%
Synthaverse S.A. 61.2 Million PLN 99.875%
Urteste S.A. 312 Thousand PLN 75.534%